微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: Experts scrutinize Huidagene’s disclosures after patient death
RSS 官方收录 · 可信分层展示
关键摘要
Want to stay on top of the science and politics driving biotech today?Sign up to get our biotech newsletter in your inbox.…
- Good morning.
- We’re sending the newsletter a bit early today since we’ve got some br…
- Merck and Moderna’s mRNA cancer vaccine succeeds in late-stage trial S…
摘要引擎：抽取
正文提要
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’re sending the newsletter a bit early today since we’ve got some breaking news for you — plus a new FDA commissioner nominee.
Merck and Moderna’s mRNA cancer vaccine succeeds in late-stage trial
Scientists have long hoped that personalized mRNA cancer vaccines could be the next big breakthrough in oncology treatment. Today, Merck and Moderna said they had shown in a randomized late-stage trial for the first time that such a drug can work.